Literature DB >> 7039511

Pityriasis rosea-like rash from captopril.

J K Wilkin, W M Kirkendall.   

Abstract

Captopril, an orally active dipeptidylcarboxypeptidase inhibitor, is a promising new antihypertensive agent. Cutaneous reactions, including (rarely) a pityriasis rosea-like eruption, are frequently associated with this therapy. Two new cases of a pityriasis rosea-like captopril-induced eruption support a pharmacologic mechanism for the eruption, since it resolved after the dosage of captopril was lowered in one patient and continued when the dosage of captopril remained unchanged in the other patient. However, the eruption later responded to therapy while use of the drug was continued. Captopril should be included among those drugs associated with a pityriasis rosea-like eruption.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7039511

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  8 in total

Review 1.  Adverse reactions with angiotensin converting enzyme (ACE) inhibitors.

Authors:  R DiBianco
Journal:  Med Toxicol       Date:  1986 Mar-Apr

2.  A Randomized, Double-blind, Placebo-Controlled Study of Efficacy of Oral Acyclovir in the Treatment of Pityriasis Rosea.

Authors:  Satyaki Ganguly
Journal:  J Clin Diagn Res       Date:  2014-05-15

3.  Pityriasis rosea and discoid eczema: dose related reactions to treatment with gold.

Authors:  S M Wilkinson; A G Smith; M J Davis; D Mattey; P T Dawes
Journal:  Ann Rheum Dis       Date:  1992-07       Impact factor: 19.103

Review 4.  Angiotensin inhibitors and other vasodilators with special reference to congestive heart failure.

Authors:  K Chatterjee; L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1987       Impact factor: 3.727

Review 5.  Captopril: an update review of its pharmacological properties and therapeutic efficacy in congestive heart failure.

Authors:  J A Romankiewicz; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-01       Impact factor: 9.546

6.  Cutaneous adverse events in multiple sclerosis patients treated with daclizumab.

Authors:  Irene Cortese; Joan Ohayon; Kaylan Fenton; Chyi-Chia Lee; Mark Raffeld; Edward W Cowen; John J DiGiovanna; Bibiana Bielekova
Journal:  Neurology       Date:  2016-02-03       Impact factor: 9.910

Review 7.  Clinical variants of pityriasis rosea.

Authors:  Francisco Urbina; Anupam Das; Emilio Sudy
Journal:  World J Clin Cases       Date:  2017-06-16       Impact factor: 1.337

8.  Cutaneous reactions to COVID-19 vaccines: A review.

Authors:  See Wei Tan; Yew Chong Tam; Shiu Ming Pang
Journal:  JAAD Int       Date:  2022-02-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.